SHPMY
Price
$7.80
Change
+$0.12 (+1.56%)
Updated
Jan 17 closing price
Capitalization
9.5B
ZYXI
Price
$8.20
Change
+$0.06 (+0.74%)
Updated
Jan 22, 04:59 PM (EDT)
Capitalization
397.95M
36 days until earnings call
Ad is loading...

SHPMY vs ZYXI

Header iconSHPMY vs ZYXI Comparison
Open Charts SHPMY vs ZYXIBanner chart's image
Shanghai Pharmaceuticals Holdings
Price$7.80
Change+$0.12 (+1.56%)
Volume$235
Capitalization9.5B
Zynex
Price$8.20
Change+$0.06 (+0.74%)
Volume$791
Capitalization397.95M
SHPMY vs ZYXI Comparison Chart
Loading...
SHPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYXI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SHPMY vs. ZYXI commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SHPMY is a Hold and ZYXI is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (SHPMY: $7.80 vs. ZYXI: $8.14)
Brand notoriety: SHPMY and ZYXI are both not notable
Both companies represent the Medical Distributors industry
Current volume relative to the 65-day Moving Average: SHPMY: 37% vs. ZYXI: 132%
Market capitalization -- SHPMY: $9.5B vs. ZYXI: $397.95M
SHPMY [@Medical Distributors] is valued at $9.5B. ZYXI’s [@Medical Distributors] market capitalization is $397.95M. The market cap for tickers in the [@Medical Distributors] industry ranges from $70.55B to $0. The average market capitalization across the [@Medical Distributors] industry is $9.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SHPMY’s FA Score shows that 0 FA rating(s) are green whileZYXI’s FA Score has 1 green FA rating(s).

  • SHPMY’s FA Score: 0 green, 5 red.
  • ZYXI’s FA Score: 1 green, 4 red.
According to our system of comparison, SHPMY is a better buy in the long-term than ZYXI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SHPMY’s TA Score shows that 1 TA indicator(s) are bullish while ZYXI’s TA Score has 3 bullish TA indicator(s).

  • SHPMY’s TA Score: 1 bullish, 5 bearish.
  • ZYXI’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, ZYXI is a better buy in the short-term than SHPMY.

Price Growth

SHPMY (@Medical Distributors) experienced а -1.27% price change this week, while ZYXI (@Medical Distributors) price change was +6.27% for the same time period.

The average weekly price growth across all stocks in the @Medical Distributors industry was +1.14%. For the same industry, the average monthly price growth was +1.42%, and the average quarterly price growth was +4.17%.

Reported Earning Dates

ZYXI is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Medical Distributors (+1.14% weekly)

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SHPMY($9.5B) has a higher market cap than ZYXI($398M). ZYXI has higher P/E ratio than SHPMY: ZYXI (46.30) vs SHPMY (8.39). ZYXI YTD gains are higher at: 1.623 vs. SHPMY (-6.419). SHPMY has higher annual earnings (EBITDA): 11.1B vs. ZYXI (17.9M). SHPMY has higher revenues than ZYXI: SHPMY (241B) vs ZYXI (184M).
SHPMYZYXISHPMY / ZYXI
Capitalization9.5B398M2,388%
EBITDA11.1B17.9M62,011%
Gain YTD-6.4191.623-395%
P/E Ratio8.3946.3018%
Revenue241B184M130,978%
Total CashN/A44.6M-
Total DebtN/A76.2M-
FUNDAMENTALS RATINGS
SHPMY vs ZYXI: Fundamental Ratings
SHPMY
ZYXI
OUTLOOK RATING
1..100
5453
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
8169
PRICE GROWTH RATING
1..100
5180
P/E GROWTH RATING
1..100
419
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SHPMY's Valuation (37) in the null industry is somewhat better than the same rating for ZYXI (95) in the Medical Specialties industry. This means that SHPMY’s stock grew somewhat faster than ZYXI’s over the last 12 months.

ZYXI's Profit vs Risk Rating (93) in the Medical Specialties industry is in the same range as SHPMY (100) in the null industry. This means that ZYXI’s stock grew similarly to SHPMY’s over the last 12 months.

ZYXI's SMR Rating (69) in the Medical Specialties industry is in the same range as SHPMY (81) in the null industry. This means that ZYXI’s stock grew similarly to SHPMY’s over the last 12 months.

SHPMY's Price Growth Rating (51) in the null industry is in the same range as ZYXI (80) in the Medical Specialties industry. This means that SHPMY’s stock grew similarly to ZYXI’s over the last 12 months.

ZYXI's P/E Growth Rating (9) in the Medical Specialties industry is in the same range as SHPMY (41) in the null industry. This means that ZYXI’s stock grew similarly to SHPMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SHPMYZYXI
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 15 days ago
67%
Bullish Trend 15 days ago
81%
Momentum
ODDS (%)
Bearish Trend 15 days ago
61%
Bearish Trend 15 days ago
76%
MACD
ODDS (%)
Bearish Trend 15 days ago
67%
Bearish Trend 15 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 15 days ago
62%
Bullish Trend 15 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 15 days ago
67%
Bullish Trend 15 days ago
84%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 17 days ago
61%
Bearish Trend 24 days ago
79%
BollingerBands
ODDS (%)
N/A
Bullish Trend 15 days ago
77%
Aroon
ODDS (%)
Bearish Trend 15 days ago
73%
Bullish Trend 15 days ago
81%
View a ticker or compare two or three
Ad is loading...
SHPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYXI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VSCAX25.150.49
+1.99%
Invesco Small Cap Value A
TPICX12.650.21
+1.69%
Timothy Plan International C
NUGCX35.200.45
+1.29%
Nuveen Global Dividend Growth C
GRMAX27.85N/A
N/A
Nationwide S&P 500 Index A
MFVSX17.05N/A
N/A
MassMutual Equity Opports R5

SHPMY and

Correlation & Price change

A.I.dvisor tells us that SHPMY and NSVGF have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SHPMY and NSVGF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SHPMY
1D Price
Change %
SHPMY100%
N/A
NSVGF - SHPMY
14%
Poorly correlated
N/A
COSM - SHPMY
12%
Poorly correlated
+8.47%
SHTDF - SHPMY
12%
Poorly correlated
N/A
ZYXI - SHPMY
7%
Poorly correlated
+5.99%
SHPMF - SHPMY
7%
Poorly correlated
N/A
More

ZYXI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYXI has been loosely correlated with OMI. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYXI jumps, then OMI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYXI
1D Price
Change %
ZYXI100%
+5.99%
OMI - ZYXI
40%
Loosely correlated
+2.33%
HSIC - ZYXI
17%
Poorly correlated
+1.32%
PDCO - ZYXI
14%
Poorly correlated
+0.16%
GEG - ZYXI
11%
Poorly correlated
+0.28%
COSM - ZYXI
10%
Poorly correlated
+8.47%
More